3 newer rulings cite the same tariff codes.

Classification can shift over time. Review the more recent rulings below before relying on this one.

N307483 N3 Ruling Active

The tariff classification of Hydroxychloroquine Sulfate Tablets in dosage form, from India

Issued November 26, 2019 by U.S. Customs and Border Protection.

Cite this ruling

Copies to clipboard

N3 N307483 (November 26, 2019)

Tariff classification

HTS codes: 3004.90.9210

Headings: 3004

Product description

Hydroxychloroquine Sulfate, imported in 200 mg tablets, is an antimalarial agent. It is primarily indicated for the treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax). Hydroxychloroquine Sulfate is also indicated for the treatment of chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis.

CBP rationale

The applicable subheading for the Hydroxychloroquine Sulfate Tablets in dosage form will be 3004.90.9210, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Anti-infective medicaments: Other.

Full text

N307483 November 26, 2019 CLA-2-30:OT:RR:NC:N3:138 CATEGORY: Classification TARIFF NO.: 3004.90.9210 Ms. Rhona M. Keeler NorthStar Healthcare 3300 Cork Airport Business Park Kinsale Road, Cork T12 XN72 Ireland RE: The tariff classification of Hydroxychloroquine Sulfate Tablets in dosage form, from India Dear Ms. Keeler: In your letter dated November 8, 2019, you requested a tariff classification ruling. Hydroxychloroquine Sulfate, imported in 200 mg tablets, is an antimalarial agent. It is primarily indicated for the treatment of uncomplicated malaria (caused by P. falciparum, P. malariae, P. ovale, or P. vivax). Hydroxychloroquine Sulfate is also indicated for the treatment of chronic discoid lupus erythematosus, systemic lupus erythematosus, acute rheumatoid arthritis, and chronic rheumatoid arthritis. The applicable subheading for the Hydroxychloroquine Sulfate Tablets in dosage form will be 3004.90.9210, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Anti-infective medicaments: Other.” The rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on the World Wide Web at https://hts.usitc.gov/current. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Judy Lee at [email protected]. Sincerely, Steven A. Mack Director National Commodity Specialist Division

View original on CBP CROSS →

More rulings on the same tariff codes

Follow N307483

Get an email if this ruling is revoked or modified, or a newer ruling supersedes it.

One email per day at most. Confirm your address once, unsubscribe anytime.

Searching CBP rulings the smart way

Rulings are precedent. See which ones apply to your product: TariffLens semantically searches all 200,000+ CBP rulings and builds defensible classifications backed by ruling citations.